Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $1,447,165.50 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Catalyst Pharmaceuticals Trading Down 1.0 %

CPRX opened at $21.67 on Friday. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 3.31 and a beta of 0.80. The stock’s 50-day moving average price is $22.27 and its 200 day moving average price is $21.49. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $24.64.

Analyst Ratings Changes

A number of research firms have recently weighed in on CPRX. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Stephens reiterated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Bank of America reissued a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $32.50.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CPRX. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $27,000. Park Square Financial Group LLC acquired a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $29,000. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares in the last quarter. Larson Financial Group LLC raised its position in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $65,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.